Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0001209191-22-054838

Chief Executive Officer sold 25,000 shares at an average $54.81 ($1,370,191)

  • Chief Executive Officer acquired 25,000 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Kulkarni Samarth Chief Executive Officer 2022-10-26 Option exercise +19,582 $16.21 $317,424 309,861 D
Kulkarni Samarth Chief Executive Officer 2022-10-26 Option exercise +5,418 $19.12 $103,592 315,279 D
Kulkarni Samarth Chief Executive Officer 2022-10-26 Sale −2,500 $52.73 $131,830 312,779 D
Kulkarni Samarth Chief Executive Officer 2022-10-26 Sale −4,000 $54.06 $216,254 308,779 D
Kulkarni Samarth Chief Executive Officer 2022-10-26 Sale −11,312 $54.97 $621,774 297,467 D
Kulkarni Samarth Chief Executive Officer 2022-10-26 Sale −7,188 $55.69 $400,333 290,279 D
Derivatives
Kulkarni Samarth Chief Executive Officer 2022-10-26 Option exercise · Stock Option (Right to Buy) −19,582 13,751 D
Kulkarni Samarth Chief Executive Officer 2022-10-26 Option exercise · Stock Option (Right to Buy) −5,418 254,582 D
Open-market sales · 25,000 sh · avg $54.81 · $1,370,191
Loading xslF345X03/doc4.xml…